About this data
What it is
ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
Who files it
The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
How current
We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
Terms
ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
Worth knowing
A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
Not to be confused with
FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.

All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.

Studies updated per day, last 30 days

0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0
0200400600Oct 17 · All industry-sponsored studies: 0Oct 17 · Sponsor matched to a public company: 0Oct 17Oct 18 · All industry-sponsored studies: 0Oct 18 · Sponsor matched to a public company: 0Oct 19 · All industry-sponsored studies: 238Oct 19 · Sponsor matched to a public company: 79Oct 20 · All industry-sponsored studies: 278Oct 20 · Sponsor matched to a public company: 92Oct 21 · All industry-sponsored studies: 244Oct 21 · Sponsor matched to a public company: 78Oct 21Oct 22 · All industry-sponsored studies: 234Oct 22 · Sponsor matched to a public company: 67Oct 23 · All industry-sponsored studies: 259Oct 23 · Sponsor matched to a public company: 93Oct 24 · All industry-sponsored studies: 0Oct 24 · Sponsor matched to a public company: 0Oct 25 · All industry-sponsored studies: 0Oct 25 · Sponsor matched to a public company: 0Oct 25Oct 26 · All industry-sponsored studies: 253Oct 26 · Sponsor matched to a public company: 70Oct 27 · All industry-sponsored studies: 283Oct 27 · Sponsor matched to a public company: 102Oct 28 · All industry-sponsored studies: 287Oct 28 · Sponsor matched to a public company: 97Oct 29 · All industry-sponsored studies: 256Oct 29 · Sponsor matched to a public company: 88Oct 29Oct 30 · All industry-sponsored studies: 252Oct 30 · Sponsor matched to a public company: 103Oct 31 · All industry-sponsored studies: 0Oct 31 · Sponsor matched to a public company: 0Nov 1 · All industry-sponsored studies: 0Nov 1 · Sponsor matched to a public company: 0Nov 2 · All industry-sponsored studies: 305Nov 2 · Sponsor matched to a public company: 99Nov 2Nov 3 · All industry-sponsored studies: 478Nov 3 · Sponsor matched to a public company: 257Nov 4 · All industry-sponsored studies: 390Nov 4 · Sponsor matched to a public company: 184Nov 5 · All industry-sponsored studies: 356Nov 5 · Sponsor matched to a public company: 143Nov 6 · All industry-sponsored studies: 338Nov 6 · Sponsor matched to a public company: 135Nov 6Nov 7 · All industry-sponsored studies: 0Nov 7 · Sponsor matched to a public company: 0Nov 8 · All industry-sponsored studies: 0Nov 8 · Sponsor matched to a public company: 0Nov 9 · All industry-sponsored studies: 309Nov 9 · Sponsor matched to a public company: 101Nov 10 · All industry-sponsored studies: 347Nov 10 · Sponsor matched to a public company: 139Nov 10Nov 11 · All industry-sponsored studies: 0Nov 11 · Sponsor matched to a public company: 0Nov 12 · All industry-sponsored studies: 576Nov 12 · Sponsor matched to a public company: 214Nov 13 · All industry-sponsored studies: 329Nov 13 · Sponsor matched to a public company: 136Nov 14 · All industry-sponsored studies: 0Nov 14 · Sponsor matched to a public company: 0Nov 14Nov 15 · All industry-sponsored studies: 0Nov 15 · Sponsor matched to a public company: 0

All industry-sponsored studies Sponsor matched to a public company

By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.

Latest clinical trial updates

Reset

Showing: ticker BCRX · All recent updates

Studies by the date their record was last updated.

Latest clinical trial updates
UpdatedStudySponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).EnrolledPrimary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.Source
Nov 10, 2026Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glom…
NCT05162066 · Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy
BCX9930
BCRX
BioCryst Pharmaceuticals
Phase 2Terminated2Sep 23, 2022Registry ↗
Nov 10, 2026BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequ…
NCT05116774 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Eculizumab, Ravulizumab
BCRX
BioCryst Pharmaceuticals
Phase 2Terminated12Sep 14, 2023Registry ↗
Nov 6, 2026A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
NCT06539507 · Netherton Syndrome
BCX17725, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 1Active, not recruiting
was recruiting
76Dec 2026Registry ↗
Oct 29, 2026BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receivin…
NCT05116787 · Paroxysmal Nocturnal Hemoglobinuria (PNH)
Placebo, BCX9930 monotherapy
BCRX
BioCryst Pharmaceuticals
Phase 2Terminated12Sep 18, 2023Registry ↗
Jun 10, 2026A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated…
NCT01224795 · Influenza
Peramivir, Placebo Comparator
BCRX
BioCryst Pharmaceuticals
Phase 3Withdrawn0Nov 2010Registry ↗
Jun 1, 2026Intramuscular Peramivir for the Treatment of Uncomplicated Influenza
NCT00486980 · Influenza
Peramivir 150mg, Peramivir 300mg
BCRX
BioCryst Pharmaceuticals
Phase 3Withdrawn0—Registry ↗
May 11, 2026A Study of Avoralstat In Participants With Diabetic Macular Edema
NCT07228559 · Diabetic Macular Edema (DME)
avoralstat
BCRX
BioCryst Pharmaceuticals
Phase 1Terminated3Apr 17, 2026Registry ↗
Feb 25, 2026Berotralstat Treatment in Children With Hereditary Angioedema
NCT05453968 · Hereditary Angioedema, Pediatric
Berotralstat
BCRX
BioCryst Pharmaceuticals
Phase 3Active, not recruiting29Sep 11, 2024Registry ↗
Dec 23, 2025Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies
NCT04933721 · Hereditary Angioedema, HAE
berotralstat
BCRX
BioCryst Pharmaceuticals
Phase 3Enrolling by invitation139Aug 2031Registry ↗
Nov 17, 202512-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks
NCT02303626 · Hereditary Angioedema, HAE
BCX4161, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 2/3Completed110Jan 2016Registry ↗
Oct 24, 2025Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria
NCT05741346 · Paroxysmal Nocturnal Hemoglobinuria
BCX9930
BCRX
BioCryst Pharmaceuticals
Phase 2Terminated28Jan 31, 2025Registry ↗
Apr 13, 2025A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04702568 · Paroxysmal Nocturnal Hemoglobinuria, PNH
BCX9930, Eculizumab
BCRX
BioCryst Pharmaceuticals
Phase 2Terminated19Oct 4, 2023Registry ↗
Jan 8, 2025Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT06100900 · Paroxysmal Nocturnal Hemoglobinuria
BCX10013
BCRX
BioCryst Pharmaceuticals
Phase 1Completed8Dec 11, 2024Registry ↗
Jul 19, 2024Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE…
NCT03873116 · Hereditary Angioedema, HAE
BCX7353 capsules, BCX7353 capsules
BCRX
BioCryst Pharmaceuticals
Phase 3Completed19Jul 8, 2021Registry ↗
Jun 26, 2023Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
NCT03485911 · Hereditary Angioedema, HAE
BCX7353 capsules, Placebo oral capsule
BCRX
BioCryst Pharmaceuticals
Phase 3Completed121Apr 10, 2019Registry ↗
Jun 18, 2023A Long Term Safety Study of BCX7353 in Hereditary Angioedema
NCT03472040 · Hereditary Angioedema, HAE
BCX7353
BCRX
BioCryst Pharmaceuticals
Phase 2/3Completed387Apr 27, 2022Registry ↗
Feb 17, 2022First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
NCT04330534 · Paroxysmal Nocturnal Hemoglobinuria
BCX9930, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 1/2Completed168Nov 11, 2020Registry ↗
Jul 23, 2021A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
NCT03800173 · Marburg Virus Disease
galidesivir, placebo
BCRX
BioCryst Pharmaceuticals
Phase 1Completed32Apr 30, 2019Registry ↗
May 27, 2021A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fev…
NCT03891420 · COVID-19, Yellow Fever
Galidesivir, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 1Terminated24Jan 31, 2021Registry ↗
Apr 1, 2021Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
NCT03240133 · Hereditary Angioedema (HAE)
BCX7353, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 2Completed58Jan 29, 2019Registry ↗
Mar 23, 2021Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
NCT02870972 · Hereditary Angioedema (HAE)
BCX7353, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 2Completed75Aug 2017Registry ↗
Mar 23, 2021Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated…
NCT02635724 · Influenza
Peramivir
BCRX
BioCryst Pharmaceuticals
Phase 3Completed74Apr 2018Registry ↗
Mar 23, 2021Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncompli…
NCT02369159 · Influenza
Peramivir, Oseltamivir
BCRX
BioCryst Pharmaceuticals
Phase 3Completed137Oct 28, 2019Registry ↗
Mar 17, 2021Intramuscular Peramivir in Subjects With Uncomplicated Acute Influenza
NCT00610935 · Influenza
Peramivir, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 3Terminated82Feb 2008Registry ↗
Dec 11, 2020Oral Berotralstat Expanded Access Program
NCT04428632 · Hereditary Angioedema, HAE
Berotralstat
BCRX
BioCryst Pharmaceuticals
—Approved for marketing——Registry ↗
Jan 27, 2020A Relative Bioavailability Study of Two Formulations of BCX7353
NCT03202784 · Hereditary Angioedema
BCX7353
BCRX
BioCryst Pharmaceuticals
Phase 1Completed24Aug 1, 2017Registry ↗
Oct 26, 2017A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
NCT03136237 · Hereditary Angioedema
BCX7353, Digoxin
BCRX
BioCryst Pharmaceuticals
Phase 1Completed54Aug 15, 2017Registry ↗
Jan 31, 2017An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzy…
NCT02819102 · Hereditary Angioedema
BCX7353 and probes
BCRX
BioCryst Pharmaceuticals
Phase 1Completed20Jun 2016Registry ↗
Jul 7, 2016A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430
NCT02319772 · Filovirus Infections, Ebola Virus Infection
BCX4430, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 1Completed94Mar 2016Registry ↗
Feb 17, 2016Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema
NCT02670720 · Hereditary Angioedema, HAE
avoralstat
BCRX
BioCryst Pharmaceuticals
Phase 3Terminated6Feb 2016Registry ↗
Jan 13, 2016First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of…
NCT02448264 · Hereditary Angioedema
BCX7353, Placebo to match BCX7353
BCRX
BioCryst Pharmaceuticals
Phase 1Completed122Nov 2015Registry ↗
Feb 16, 2015A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety…
NCT00705406 · Acute, Uncomplicated Human Influenza
Peramivir, Placebo
BCRX
BioCryst Pharmaceuticals
Phase 2Completed405Apr 2009Registry ↗
Feb 12, 2015A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compare…
NCT00958776 · Cough, Sore Throat
Peramivir+SOC, Placebo+SOC
BCRX
BioCryst Pharmaceuticals
Phase 3Terminated405Nov 2012Registry ↗
Feb 12, 2015Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
NCT00957996 · Seasonal Influenza, Cough
Peramivir, Peramivir
BCRX
BioCryst Pharmaceuticals
Phase 3Completed234Oct 2010Registry ↗
Feb 12, 2015Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-thr…
NCT00453999 · Influenza
Peramivir 200 mg, Peramivir 400 mg
BCRX
BioCryst Pharmaceuticals
Phase 2Completed137Sep 2008Registry ↗
Feb 12, 2015Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.
NCT00419263 · Influenza
Peramivir 150 mg, Peramivir 300 mg
BCRX
BioCryst Pharmaceuticals
Phase 2Completed344Sep 2007Registry ↗

36 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:47 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances